Increased intratumor Vα24-positive natural killer T cells: A prognostic factor for primary colorectal carcinomas

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7322-7327

  Tachibana, Tsuyoshi ^a   Onodera, Hisashi ^a   Tsuruyama, Tatsuaki ^a   Mori, Akira ^a   Nagayama, Satoshi ^a   Hiai, Hiroshi ^b   Imamura, Masayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Shiga Medical Center for Adults   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR VALPHA24; UNCLASSIFIED DRUG; CD161 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; LECTIN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; JAPAN; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; COLORECTAL TUMOR; IMMUNOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; SURVIVAL;

AGED; ANTIGENS, CD56; ANTIGENS, CD57; ANTIGENS, SURFACE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KILLER CELLS, NATURAL; LECTINS, C-TYPE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 27144471372     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0877     Document Type: Article

References (43)

1. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003:21:483-513.
2. - α/β T cells demonstrates preferential use of several Vβ genes and an invariant TCRα chain. J Exp Med 1993;178:1-16.
3. - T cells. J Exp Med 1994;180:1171-6.
4. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997;15:535-62.
5. Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998;188:1521-8.
6. Exley M, Porcelli S, Furman M, et al. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24JαQ T-cell receptor a chains. J Exp Med 1998;188:867-76.
7. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
8. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998;188:1529-34.
9. +NK T lymphocytes. J Immunol 1998;161:3271-81.
10. Godfrey DI, Hammond KJ, Poulton LD, et al. NKT cells: Facts, functions, and fallacies. Immunol Today 2000;21:573-83.
11. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human Vα24 natural killer T cells. J Exp Med 2002;195:637-41.
12. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-20.
13. + natural killer T cells in the innate phase of host protection against Streptococcus pneumonias infection. Eur J Immunol 2003;33:3322-30.
14. Kawakami K, Kinjo Y, Uezu K, et al. Monocyte chemoattractant protein-1-dependent increase of Vα14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J Immunol 2001;167:6525-32.
15. Grubor-Bauk B, Simmons A, Mayrhofer G, Speck PG. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant Vα14-Jα281 TCR. J Immunol 2003;170:1430-4.
16. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cell. Immunity 2002;17:629-38.
17. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7.
18. Ito K, Karasawa M, Kawano T, et al. Involvement of decidual Vα14 NKT cells in abortion. Proc Natl Acad Sci U S A 2000;97:740-4.
19. Seino K, Fukao K, Muramoto K, et al. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci U S A 2001;98:2577-81.
20. Ikehara Y, Yasunami Y, Kodama S, et al. CD4+Vα14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J Clin Invest 2000;105:1761-7.
21. Hammond KJL, Godfrey DI. NKT cells: Potential targets for autoimmune disease therapy? Tissue Antigens 2002;59:353-63.
22. Beaudoin L, LalouzV, Novak J, et al. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic B cells. Immunity 2002;17:725-36.
23. Hong S, Wilson MT, Serizawa I, et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001;7:1052-6.
24. Kita H, Naidenko OV, Kronenberg M, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002;123:1031-43.
25. Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003;9:582-8.
26. Araujo LM, Lefort J, Nahori MA, et al. Exacerbated Th2-mediated airway inflammation and hyperresponsiveness in autoimmune diabetes-prone NOD mice: a critical role for CD1d-dependent NKT cells. Eur J Immunol 2004;34:327-35.
27. Smyth MJ, Crowe NY, Hayakawa Y, et al. NKT cells: conductors of tumor immunity? Curr Opin Immunol 2002;14:165-71.
28. Cui J, Shin T, Kawano T, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-6.
29. Kawano T, Cui J, Koezuka Y, et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc Natl Acad Sci U S A 1998;95:5690-3.
30. Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-8.
31. Kawano T, Nakayama T, Kamada N, et al. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res 1999;59:5102-5.
32. + NKT cells against melanoma. Br J Cancer 2001;85:741-6.
33. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196:119-27.
34. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557-68.
35. + natural killer T cells in the large intestine. Eur J Immunol 2001;31:3361-9.
36. O'Keeffe J, Doherty DG, Kenna T, et al. Diverse populations of T cells with NK cell receptors accumulate in the healthy human intestine and in colorectal cancer. Eur J Immunol 2004;34:2110-8.
37. Sobin LH, Wittekind CH. In: UICC TNM classification of malignant tumors. 5th ed. New York: Wiley & Liss; 1997. p. 66-9.
38. Rass JR, Sobin LH. Histological typing of intestinal tumors. In: WHO. International histological classification of tumors. 2nd ed. Berlin: Springer-Verlag; 1988. p. 1-127.
39. Japanese Society for Cancer of the Colon and Rectum. In: General rules for clinical and pathological studies on cancer of the colon, rectum, and anus: Part VI. Tokyo: Kanehara and Co.; 1998. p. 8-29.
40. Godfrey DI, MacDonald HR, Kronenberg M, et al. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-7.
41. Tahir SMA, Cheng O, Shaulov A, et al. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-50.
42. Schwemmer B. Natural killer T cells in patients with prostatic carcinoma. Urol Int 2003;71:146-9.
43. Coca S, Perez-Piqueras J, Martinez D, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997;79:2320-8.